89280-24-0Relevant academic research and scientific papers
Heterocyclic Adenosine Receptor Antagonists
-
Paragraph 0249; 0250-0251, (2021/09/26)
Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein. Also disclosed herein are pharmaceutical compositions and methods of administration of
Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a] pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors
Sanchez, Robert M.,Erhard, Karl,Hardwicke, Mary Ann,Lin, Hong,McSurdy-Freed, Jeanelle,Plant, Ramona,Raha, Kaushik,Rominger, Cynthia M.,Schaber, Michael D.,Spengler, Michael D.,Moore, Michael L.,Yu, Hongyi,Luengo, Juan I.,Tedesco, Rosanna,Rivero, Ralph A.
scheme or table, p. 3198 - 3202 (2012/06/29)
A series of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones with excellent enzyme inhibition, improved isoform selectivity, and excellent inhibition of downstream phosphorylation of AKT has been identified. Several compounds in the series demonstrated potent (～ 0.100 μM IC50) growth inhibition in a PTEN deficient cancer cell line.
SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES
-
Page/Page column 36, (2010/05/13)
The invention relates to substituted imidazopyrimidines and triazolopyrimidines, to methods for the production thereof, and to the use of same for producing medicaments for the treatment and/or prophylaxis of diseases, especially haematological diseases, preferably leucopenia and neutropenia.
